In the news

According to the CFIA Groupe Manufacturier Metro Inc. recalled Adonis brand Classic Hummus because of microbial contamination, specifically yeast. The products were sold in 250 g containers. The recalled products were distributed in the Canadian provinces of Ontario and Quebec. @ https://recalls-rappels.canada.ca/en/alert-recall/adonis-brand-classic-hummus-recalled-due-yeast

In Israel, the importer Gold Frost Ltd. recalled from the marketplace Edema – green soybeans frozen in pods from Wily Food brand – green soybeans in frozen pods 1 kg due to Listeria monocytogenes. The product was manufactured by Zeinzg Kingshore Foods Co Ltd – China. The recall is coordinated with the food service, Central District of the Ministry of Health.@ https://kswfoodmicro.com/2024/04/04/israel-frozen-green-soyabeans-in-pods-listeria-monocytogenes/

The CDC reported that the outbreak of Salmonella in Charcuterie meats is over. A total of 104 people were infected with the outbreak strain of Salmonella, and 27 were hospitalized In 33 states. Illnesses started from November 20, 2023, to February 10, 2024. Of 92 people with information available, 27 were hospitalized. No deaths were reported. Of 68 people interviewed, 50 (74%) sick people reported eating a variety of charcuterie meats. 25 people provided specific information or shopper card records, all of which reported brands of charcuterie meats produced by Fratelli Beretta. The outbreak strain was found in one package of Fratelli Beretta charcuterie products. The outbreak investigation is over but recalled products have a six-month shelf life. The recalled products were sold nationwide under many brands, including Aldi, Beretta, Black Bear, Busseto, Culinary Tour, Dietz and Watson, Lidl, Publix, and Salumi Artigianali. @ https://www.cdc.gov/salmonella/charcuterie-meats-01-24/index.html

On April 03, 2024, the FDA approved Zevtera (ceftobiprole medocaril sodium for injection) for the treatment of adults with Staphylococcus aureus in bacteremia (SAB), including those with right-sided infective endocarditis; adults with acute bacterial skin and skin structure infections (ABSSSI); and adult and pediatric patients three months to less than 18 years old with community-acquired bacterial pneumonia (CABP). Today’s approval of Zevtera  in pediatric patients three months to less than 18 years with CABP was supported by evidence from the CABP trial of Zevtera in adults and a trial in 138 pediatric subjects three months to less than 18 years of age with pneumonia. Patients should not use Zevtera if they have a history of severe hypersensitivity to ceftobiprole, any of the components of Zevtera, or other members of the cephalosporin antibacterial class. Zevtera was granted Priority Review, Fast Track, and Qualified Infectious Disease Product designations for the CABP, ABSSSI, and SAB indications. @ https://www.fda.gov/news-events/press-announcements/fda-approves-new-antibiotic-three-different-uses?utm_medium=email&utm_source=govdelivery